You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023378033
Dec 202321205
Jan 20244303
Feb 20247206
Mar 202410603
Apr 2024114010
May 20249003
Jun 20245801
Jul 20247203
Aug 202410403
Sep 20249208
Oct 202411803
Nov 20249609
Dec 20249008
Jan 202511209
Feb 20252406
Mar 2025007
Apr 2025004
May 2025004
Jun 2025104
Total17820132